Ann: US Clinical Trial Results Published, page-28

If there wasn't such a delay between that initial peak and these results today the price wouldnt even be below 20. It's a shame that the stock is being brought down by those who achieved that quick 40% flip. NTI has nothing to do with AXP. The NTI device is basically the only device that parents can use for their autistic children. AXP has a product which is supposedly better, but requires physicians to be trained and those same people are difficult to sway from their traditional practice. The NTI device can be bought by anyone and depending on the severity of their child's autism, I'm sure that there would be many parents willing to try anything new. This will be a superstar stock!